Sales update

RNS Number:3254Q
Tepnel Life Sciences PLC
30 September 2003



FOR IMMEDIATE RELEASE

                                                               30 September 2003



Tepnel Life Sciences PLC ('Tepnel') makes US breakthrough with sale of third '
                Nucleopure' Automated DNA Purification System

                   Major US Biotech chooses 'Nucleopure'

Manchester, UK. 30 September 2003...Tepnel Life Sciences PLC (AIM: TED)
announces today that it has placed its third Nucleopure automated DNA
purification system. The system has been sold to a 'top five' US biotech and
delivery will be in October.

This customer will use the system and associated reagents for the extraction,
recovery and purification of genomic DNA from a variety of tissues and cell
culture samples as part of its research into potential new treatments for human
diseases.

Nucleopure is a dedicated system that can extract DNA from 192 tissue samples in
30 minutes. Using conventional chemistry and manual purification techniques this
process could take a skilled technician more than one week.

Commenting today, Ben Matzilevich, Tepnel's CEO, said: "Breaking into the US
market with Nucleopure, as we forecast earlier this year, is a great
achievement. The purchase of our Nucleopure system by this leading biotech
company is extremely encouraging. We believe it demonstrates the value of our
automated DNA purification systems to the drug discovery process.

The high throughput capabilities of the Nucleopure system are especially
important to large pharmaceutical companies, which may process thousands of
samples a month and cannot sacrifice either yield or purity. Nucleopure
instrument sales will generate a significant ongoing revenue stream, given the
large amounts of reagents that are consumed by this closed system."

                                     -ends-

Further enquiries

Tepnel Life Sciences - 0161 946 2200
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director

De Facto Communications - 020 7496 3300
Richard Anderson


Notes to Editors

Tepnel Life Sciences is a global biotechnology company with a "tripolar"
strategy focused on providing the biomedical industry with high-throughput
automated DNA purification systems, manual DNA purification kits and reagents,
as well as scientific services for nucleic acid purification, drug analysis,
genotyping and genetically modified foods (GMOs).

The Company was founded in 1992 to exploit DNA technology generated at UMIST
(University of Manchester Institute of Science and Technology) and is listed on
the AIM segment of the London Stock Exchange (AIM: TED).


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCNKCKDBBKBCCB